Remdesivir treatment for patients with moderate to severe COVID-19

Imran Hasanoğlu; Rahmet Güner; Ilhami Çelik; Fikret Kanat; Ayşe Batirel; Gülçin Telli Dizman; Esma Eren; Dilek Yildiz Sevgi; Ilkay Bozkurt; Kadriye Kart Yaşar; Sevtap Şenoğlu; Esra Kazak; Ridvan Karaali; Aysel Çelikbaş; Hüsnü Pullukçu; Arif Atahan Çağatay; Serhat Ünal; Şebnem Erdinç; Fehmi Tabak; Ahmet Gül; Emine Alp

doi:10.55730/1300-0144.5387

Remdesivir treatment for patients with moderate to severe COVID-19

Imran Hasanoğlu, Rahmet Güner, Ilhami Çelik, Fikret Kanat, Ayşe Batirel, Gülçin Telli Dizman, Esma Eren, Dilek Yildiz Sevgi, Ilkay Bozkurt, Kadriye Kart Yaşar, Sevtap Şenoğlu, Esra Kazak, Ridvan Karaali, Aysel Çelikbaş, Hüsnü Pullukçu, Arif Atahan Çağatay, Serhat Ünal, Şebnem Erdinç, Fehmi Tabak, Ahmet GülEmine Alp

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Background/aim: Remdesivir, which was first developed for the treatment of Ebola disease but failed to meet expectations, has become hope in the fight against the COVID-19 pandemic. This study aimed to evaluate risk factors for mortality and prognosis of adult moderate/severe COVID-19 patients treated with remdesivir, and safety and tolerability of 5 days of remdesivir treatment. Materials and methods: This multicenter prospective observational study was conducted in 14 centers in Turkey. Pregnancy or breastfeeding, multiorgan failure, or usage of vasopressors for septic shock, ALT > 5 × the upper limit of the normal range, or eGRF <30 mL/min or dialysis and receiving favipiravir were the exclusion criteria of the study. Results: Among 500 patients, 494 patients were included in the study. On admission, 392 (79.3%) patients had moderate and 102 (20.6%) patients had severe COVID-19. The 28-day mortality was 10.1%. The median of the scores of the seven-category ordinal scale assessed on days 0, 3, 5, 7 were 4 and 3 on day 14. When the survival status of the patients was evaluated according to the time between the remdesivir start date and the end date of the symptoms, no statistically significant difference was found between the medians of the groups (p = 0.404). In multivariable analysis, age (OR, 1.05; 95%CI, 1.02–1.08; p = 0.003), SpO2 level on admission (OR, 3.03; 95%CI, 1.35–6.81; p = 0.007), heart rate (OR, 2.48; 95%CI, 1.01–6.07; p = 0.047), follow-up site at the hospital (clinic/ICU) (OR, 26.4; 95%CI, 11.6–60.17; p < 0.001) were independently associated with increased mortality. Grade 3 adverse event (AE) was observed in 4 (0.8%) patients. None of the patients experienced grade 4 or 5 AEs. Conclusion: Remdesivir is a safe and well-tolerated drug and older age, low SpO2 level on admission, tachycardia, and ICU admission are independently associated with increased mortality among patients with moderate/severe COVID-19 receiving remdesivir treatment.

Original language	English
Pages (from-to)	880-887
Number of pages	8
Journal	Turkish Journal of Medical Sciences
Volume	52
Issue number	4
DOIs	https://doi.org/10.55730/1300-0144.5387
Publication status	Published - 1 Jan 2022
Externally published	Yes

Keywords

antiviral
COVID-19
mortality
remdesivir
treatment

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.55730/1300-0144.5387

Cite this

Hasanoğlu, I., Güner, R., Çelik, I., Kanat, F., Batirel, A., Dizman, G. T., Eren, E., Sevgi, D. Y., Bozkurt, I., Yaşar, K. K., Şenoğlu, S., Kazak, E., Karaali, R., Çelikbaş, A., Pullukçu, H., Çağatay, A. A., Ünal, S., Erdinç, Ş., Tabak, F., ... Alp, E. (2022). Remdesivir treatment for patients with moderate to severe COVID-19. Turkish Journal of Medical Sciences, 52(4), 880-887. https://doi.org/10.55730/1300-0144.5387

@article{f2cdeb146e894fea84d919bce4e1f2bf,

title = "Remdesivir treatment for patients with moderate to severe COVID-19",

abstract = "Background/aim: Remdesivir, which was first developed for the treatment of Ebola disease but failed to meet expectations, has become hope in the fight against the COVID-19 pandemic. This study aimed to evaluate risk factors for mortality and prognosis of adult moderate/severe COVID-19 patients treated with remdesivir, and safety and tolerability of 5 days of remdesivir treatment. Materials and methods: This multicenter prospective observational study was conducted in 14 centers in Turkey. Pregnancy or breastfeeding, multiorgan failure, or usage of vasopressors for septic shock, ALT > 5 × the upper limit of the normal range, or eGRF <30 mL/min or dialysis and receiving favipiravir were the exclusion criteria of the study. Results: Among 500 patients, 494 patients were included in the study. On admission, 392 (79.3\%) patients had moderate and 102 (20.6\%) patients had severe COVID-19. The 28-day mortality was 10.1\%. The median of the scores of the seven-category ordinal scale assessed on days 0, 3, 5, 7 were 4 and 3 on day 14. When the survival status of the patients was evaluated according to the time between the remdesivir start date and the end date of the symptoms, no statistically significant difference was found between the medians of the groups (p = 0.404). In multivariable analysis, age (OR, 1.05; 95\%CI, 1.02–1.08; p = 0.003), SpO2 level on admission (OR, 3.03; 95\%CI, 1.35–6.81; p = 0.007), heart rate (OR, 2.48; 95\%CI, 1.01–6.07; p = 0.047), follow-up site at the hospital (clinic/ICU) (OR, 26.4; 95\%CI, 11.6–60.17; p < 0.001) were independently associated with increased mortality. Grade 3 adverse event (AE) was observed in 4 (0.8\%) patients. None of the patients experienced grade 4 or 5 AEs. Conclusion: Remdesivir is a safe and well-tolerated drug and older age, low SpO2 level on admission, tachycardia, and ICU admission are independently associated with increased mortality among patients with moderate/severe COVID-19 receiving remdesivir treatment.",

keywords = "antiviral, COVID-19, mortality, remdesivir, treatment",

author = "Imran Hasanoğlu and Rahmet G{\"u}ner and Ilhami {\c C}elik and Fikret Kanat and Ay{\c s}e Batirel and Dizman, \{G{\"u}l{\c c}in Telli\} and Esma Eren and Sevgi, \{Dilek Yildiz\} and Ilkay Bozkurt and Ya{\c s}ar, \{Kadriye Kart\} and Sevtap {\c S}enoğlu and Esra Kazak and Ridvan Karaali and Aysel {\c C}elikba{\c s} and H{\"u}sn{\"u} Pulluk{\c c}u and {\c C}ağatay, \{Arif Atahan\} and Serhat {\"U}nal and {\c S}ebnem Erdin{\c c} and Fehmi Tabak and Ahmet G{\"u}l and Emine Alp",

year = "2022",

month = jan,

day = "1",

doi = "10.55730/1300-0144.5387",

language = "English",

volume = "52",

pages = "880--887",

journal = "Turkish Journal of Medical Sciences",

issn = "1300-0144",

publisher = "TUBITAK",

number = "4",

}

Hasanoğlu, I, Güner, R, Çelik, I, Kanat, F, Batirel, A, Dizman, GT, Eren, E, Sevgi, DY, Bozkurt, I, Yaşar, KK, Şenoğlu, S, Kazak, E, Karaali, R, Çelikbaş, A, Pullukçu, H, Çağatay, AA, Ünal, S, Erdinç, Ş, Tabak, F, Gül, A & Alp, E 2022, 'Remdesivir treatment for patients with moderate to severe COVID-19', Turkish Journal of Medical Sciences, vol. 52, no. 4, pp. 880-887. https://doi.org/10.55730/1300-0144.5387

TY - JOUR

T1 - Remdesivir treatment for patients with moderate to severe COVID-19

AU - Hasanoğlu, Imran

AU - Güner, Rahmet

AU - Çelik, Ilhami

AU - Kanat, Fikret

AU - Batirel, Ayşe

AU - Dizman, Gülçin Telli

AU - Eren, Esma

AU - Sevgi, Dilek Yildiz

AU - Bozkurt, Ilkay

AU - Yaşar, Kadriye Kart

AU - Şenoğlu, Sevtap

AU - Kazak, Esra

AU - Karaali, Ridvan

AU - Çelikbaş, Aysel

AU - Pullukçu, Hüsnü

AU - Çağatay, Arif Atahan

AU - Ünal, Serhat

AU - Erdinç, Şebnem

AU - Tabak, Fehmi

AU - Gül, Ahmet

AU - Alp, Emine

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Background/aim: Remdesivir, which was first developed for the treatment of Ebola disease but failed to meet expectations, has become hope in the fight against the COVID-19 pandemic. This study aimed to evaluate risk factors for mortality and prognosis of adult moderate/severe COVID-19 patients treated with remdesivir, and safety and tolerability of 5 days of remdesivir treatment. Materials and methods: This multicenter prospective observational study was conducted in 14 centers in Turkey. Pregnancy or breastfeeding, multiorgan failure, or usage of vasopressors for septic shock, ALT > 5 × the upper limit of the normal range, or eGRF <30 mL/min or dialysis and receiving favipiravir were the exclusion criteria of the study. Results: Among 500 patients, 494 patients were included in the study. On admission, 392 (79.3%) patients had moderate and 102 (20.6%) patients had severe COVID-19. The 28-day mortality was 10.1%. The median of the scores of the seven-category ordinal scale assessed on days 0, 3, 5, 7 were 4 and 3 on day 14. When the survival status of the patients was evaluated according to the time between the remdesivir start date and the end date of the symptoms, no statistically significant difference was found between the medians of the groups (p = 0.404). In multivariable analysis, age (OR, 1.05; 95%CI, 1.02–1.08; p = 0.003), SpO2 level on admission (OR, 3.03; 95%CI, 1.35–6.81; p = 0.007), heart rate (OR, 2.48; 95%CI, 1.01–6.07; p = 0.047), follow-up site at the hospital (clinic/ICU) (OR, 26.4; 95%CI, 11.6–60.17; p < 0.001) were independently associated with increased mortality. Grade 3 adverse event (AE) was observed in 4 (0.8%) patients. None of the patients experienced grade 4 or 5 AEs. Conclusion: Remdesivir is a safe and well-tolerated drug and older age, low SpO2 level on admission, tachycardia, and ICU admission are independently associated with increased mortality among patients with moderate/severe COVID-19 receiving remdesivir treatment.

AB - Background/aim: Remdesivir, which was first developed for the treatment of Ebola disease but failed to meet expectations, has become hope in the fight against the COVID-19 pandemic. This study aimed to evaluate risk factors for mortality and prognosis of adult moderate/severe COVID-19 patients treated with remdesivir, and safety and tolerability of 5 days of remdesivir treatment. Materials and methods: This multicenter prospective observational study was conducted in 14 centers in Turkey. Pregnancy or breastfeeding, multiorgan failure, or usage of vasopressors for septic shock, ALT > 5 × the upper limit of the normal range, or eGRF <30 mL/min or dialysis and receiving favipiravir were the exclusion criteria of the study. Results: Among 500 patients, 494 patients were included in the study. On admission, 392 (79.3%) patients had moderate and 102 (20.6%) patients had severe COVID-19. The 28-day mortality was 10.1%. The median of the scores of the seven-category ordinal scale assessed on days 0, 3, 5, 7 were 4 and 3 on day 14. When the survival status of the patients was evaluated according to the time between the remdesivir start date and the end date of the symptoms, no statistically significant difference was found between the medians of the groups (p = 0.404). In multivariable analysis, age (OR, 1.05; 95%CI, 1.02–1.08; p = 0.003), SpO2 level on admission (OR, 3.03; 95%CI, 1.35–6.81; p = 0.007), heart rate (OR, 2.48; 95%CI, 1.01–6.07; p = 0.047), follow-up site at the hospital (clinic/ICU) (OR, 26.4; 95%CI, 11.6–60.17; p < 0.001) were independently associated with increased mortality. Grade 3 adverse event (AE) was observed in 4 (0.8%) patients. None of the patients experienced grade 4 or 5 AEs. Conclusion: Remdesivir is a safe and well-tolerated drug and older age, low SpO2 level on admission, tachycardia, and ICU admission are independently associated with increased mortality among patients with moderate/severe COVID-19 receiving remdesivir treatment.

KW - antiviral

KW - COVID-19

KW - mortality

KW - remdesivir

KW - treatment

U2 - 10.55730/1300-0144.5387

DO - 10.55730/1300-0144.5387

M3 - Article

SN - 1300-0144

VL - 52

SP - 880

EP - 887

JO - Turkish Journal of Medical Sciences

JF - Turkish Journal of Medical Sciences

IS - 4

ER -

Remdesivir treatment for patients with moderate to severe COVID-19

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this